title: Flow rates and inorganic composition of whole saliva in purging bulimic patients treated with a fluoxetine.
abstract: OBJECTIVE
  The current study established whether vomiting bulimic and/or non-bulimic depressive patients, both treated with a serotonin reuptake inhibitor (fluoxetine), have changes in their whole salivary secretion and inorganic components: Na(+), K(+), Ca(2+).
  
  
  METHODS
  From 108 female subjects, namely bulimics (Group B) (fluoxetine: 40 mg/day) (n=33), non-bulimic depressives (Group D) (fluoxetine: 20 mg/day) (n=25) and a Group C of 50 healthy controls, unstimulated and stimulated saliva was collected. The concentrations of Na(+), K(+), Ca(2+) were determined by colorimetric photometry method (Effox 5053, Eppendorf, Germany).
  
  
  RESULTS
  The bulimic group reported significant lower output in salivary flow and sodium concentration. In the group (D) only flow was lower than in healthy controls but not significant.
  
  
  CONCLUSIONS
  This study supports the hypothesis that salivary flow is an unreliable indicator of bulimia, the lack of increase in sodium level in stimulated saliva in bulimic subjects could be a more reliable confirmation of the eating disorder.
authors.affiliation: Department of Biomaterials and Experimental Dentistry, University of Medical Sciences, Poznan, Poland. ela@pa.pl
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Paszynska
authors.forename: Roger W A
authors.initials: RW
authors.lastname: Linden
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Slopien
authors.forename: Andrzej
authors.initials: A
authors.lastname: Rajewski
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D002032:Bulimia / Q000150:complications* / Q000175:diagnosis / Q000378:metabolism; D002118:Calcium / Q000032:analysis; D003124:Colorimetry; D003863:Depression / Q000150:complications* / Q000188:drug therapy*; D004573:Electrolytes / Q000032:analysis / Q000378:metabolism*; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D011188:Potassium / Q000032:analysis; D012463:Saliva / Q000737:chemistry* / Q000378:metabolism; D012472:Salivation / Q000187:drug effects*; D012636:Secretory Rate / Q000187:drug effects; D012964:Sodium / Q000032:analysis; D014839:Vomiting / Q000150:complications; D055815:Young Adult
chemical_list: D018687:Antidepressive Agents, Second-Generation; D004573:Electrolytes; D005473:Fluoxetine; D012964:Sodium; D011188:Potassium; D002118:Calcium